$PMCB Cancer Treatments

BALTIMORE, Apr. 7, 2015 /PRNewswire/ — Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visitwww.GoldmanResearch.com.

In the article on the Company, analyst Rob Goldman outlines the impact of the FDA’s recent moves on the biotech industry and the Company’s standing.

“Biotech stocks have been on fire since the start of 2015 and there is no sign of the money flows abating anytime soon. The primary driver behind the rise in biotechs may be the Federal Drug Administration (FDA) itself.  Last year, it approved 41 new drugs which, according to the organization’s website, were the most in nearly 20 years. That figure is up from 27 in 2013—a 51% increase year-over-year.  Could it be that the FDA has become more accommodating in its goal of more swiftly approving drugs for treatment of diseases, especially those that are rare and serious diseases?  It certainly seems that quality of life, especially in the treatment of life-threatening diseases has emerged as a key determining factor, which sets up very nicely for PharmaCyte Biotech.”

Goldman further noted, “Of the 41 approved drugs, eight were to treat cancer and four to treat type-2 diabetes. However, 17 (41%) of the drugs were approved to treat rare diseases that affect 200,000 or fewer Americans. In fact, that figure is the highest yearly total of such drugs ever — even surpassing the previous high of 13 from 2012.   That is a great sign for companies such as PharmaCyte Biotech which is right in this sweet spot. The Company’s flagship technology, Cell-in-a-Box®, has recently been granted this Orphan Drug Status by the FDA for the treatment of advanced, inoperable pancreatic cancer when used in combination with the chemotherapy drug ifosfamide at one-third the dose normally given.”

“Moreover, half of the approved drugs were fast track or breakthrough and nearly two-thirds were designated for Priority Review, meaning that the FDA saw potential for providing a significant advance in medical care, and set their review target to within six instead of the standard 10 months. Clearly this enhanced approach by the FDA has had a great impact on biotech stocks and bodes well for companies like PharmaCyte Biotech, should they be entered into any of the accelerated review tracks above.   In any event, the FDA’s current accommodative stance should continue to serve as a biotech stock driver going forward.”

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc.  The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission https://www.sec.gov.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was recently compensated by a third party in the amount of $4000 for investment research services and has been compensated $2500 for the publication of a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB – PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found atwww.PharmaCyteBiotech.com.

Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
rob@goldmanresearch.com

To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/fdas-record-approvals-bode-well-for-pharmacytes-cancer-treatments-300061877.html